Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we talk with NervGen leaders Adam Rogers, M.D., and Rich Macary about NVG-291, a daily neuroreparative peptide designed to restore function in patients with spinal cord injuries. Adam talks about his strategy for the company after becoming CEO last July, including moving company trading from Canada's TSX Venture Exchange to the NASDAQ for better visibility, and making key hires for growt...
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Business Of Biotech
The Impact Of FDA Risk On Biotech Rewards With CFO And Board Director Allan Shaw
Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.
Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor
Investing In Early-Stage Oncology With Yosemite's Dan McHugh
Get summaries like this every morning.
Free AI-powered recaps of Business Of Biotech and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.